The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost-minimization analysis (CMA) of capecitabine plus oxaliplatin (XELOX) compared with modified FOLFOX6 (mFOLFOX6) for the adjuvant treatment of resected colon cancer in British Columbia.
S. Yunger
Employment or Leadership Position - Roche
Stock Ownership - Roche
B. Mistry
Employment or Leadership Position - Roche
Stock Ownership - Roche
W. Y. Cheung
No relevant relationships to disclose
D. Ksienski
No relevant relationships to disclose
A. Urspruch
Employment or Leadership Position - Roche